The application of lanreotide autogel for the treatment of acromegaly

Cover Page


The early diagnosis of acromegaly and timely initiation of the adequate treatment are of primary importance for the prevention of the undesired long-term effects of chronic overproduction of growth hormone and insulin-like growth factor-1. Over half of the patients presenting with acromegaly are in need of sustainable treatment with somatostatin analogs that reduces the risk of premature death and helps to maintain quality of life. The new somatostatin analog lanreotide autogel recently introduced into clinical practice is known to effectively diminish secretion of both growth hormone and insulin-like growth factor-1. Moreover, it shows the ability to decrease the volume of somatotropinoms and is well tolerated by the patients. The intervals between injections of lanreotide autogel can be prolonged from 4 to 6-8 weeks. Its subcutaneous administration is technically easy which enables the majority of the patients to perform self-injections. Taken together, these advantages of lanreotide autogel considerably extend the opportunities for medical aid to the patients with acromegaly.

I A Ilovaĭskaia


  1. Colao A., Ferone D., Marzullo P., Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25:1:102-152.
  2. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006;355:24:2558-2573.
  3. Dekkers O.M., Biermasz N.R., Pereira A.M. et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008;93:1:61-67.
  4. Bates A.S., Van't Hoff W., Jones J.M., Clayton R.N. An audit of outcome of treatment in acromegaly. Q J Med 1993;86:5:293-299.
  5. Díez J.J., Iglesias P., Gómez-Pan A. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide. J Endocrinol Inv 2001;24:5:303-309.
  6. Carmichael J.D., Bonert V.S., Mirocha J.M., Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 2009;94:2:523-527.
  7. Kaltsas G.A., Isidori A.M., Florakis D. et al. Predictors of outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 2001;86:4:1645-1652.
  8. Nomikos P., Buchfelder M., Fahlbusch R. The outcome of surgery in 688 patients with acromegaly using current criteria of biochemical cure. Eur J Endocrinol 2005;152:3:379-387.
  9. Brazeau P., Vale W., Burgus R. et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:68:77-79.
  10. Patel Y.C. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:3:157-198.
  11. Danila D.C., Haidar J.N., Zhang X. et al. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotrophs tumors. J Clin Endocrinol Metab 2001;86:7:2976-2981.
  12. Lamberts S.W., Oosterom R., Neufeld M., del Pozo E. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 1985;60:6:1161-1165.
  13. Kuhn J.M., Legrand A., Ruiz J.M. et al. Pharmacokinetic and pharmacodynamic properties of long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994;38:3:213-219.
  14. Hofland L.J., Lamberts S.W. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:1:28-47.
  15. Bronstein M., Musolino N., Jallad R. et al. Pharmacokinetic profile of lanretiode Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol 2005;63:5:514-519.
  16. Newman C.B., Melmed S., Snyder P.J. et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab 1995;80:9:2768-2775.
  17. Heron I., Thomas F., Dero M. et al. Pharmacokinetics and efficacy of long-acting formulation of new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993;76:3:721-727.
  18. Antonijoan R.M., Barbanoj M.J., Cordero J.A. et al. Pharmacokinetics of a new Autogel formulataion of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol 2004;56:4:471-476.
  19. Melmed S., Casanueva F., Cavagnini F. et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:6:737-740.
  20. Bevan J.S., Newell-Price J., Wass J.A. et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxford) 2008;63:3:343-349.
  21. Caron P., Beckers A., Cullen D.R. et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87:1:99-104.
  22. Caron P., Cogne M., Raingeard I. et al. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxford) 2006;64:2:209-214.
  23. Lucas T., Astorga R. Spanish-Portuguese Multicentre Autogel study group on acromegaly. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxford) 2006;65:3:320-326.
  24. Gutt B., Bidlingmaier M., Kretschmar K. et al. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes 2005;113:3:139-144.
  25. Attanasio R., Lanzi R., Losa M. et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 2008;14:7:846-855.
  26. Melmed S., Cook D., Schopohl J. et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010;13:1:18-28.
  27. Colao A., Auriemma R.S., Rebora A. et al. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxford) 2009;71:2:237-245.
  28. Wuster C., Both S., Cordes U. et al. Primary treatment of acromegaly with high-dose lanreotide: a case series. J Med Case Reports 2010;4:85.
  29. Auriemma R.S., Galdiero M., Grasso L.F. et al. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. Eur J Endocrinol 2010;162:5:993-999.
  30. Ashwell S.G., Bevan J.S., Edwards O.M. et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004;150:4:473-480.
  31. van Thiel S.W., Romijn J.A., Biermasz N.R. et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004;150:4:489-495.
  32. Andries M., Glintborg D., Kvistborg A. et al. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-1 in patients with acromegaly. Clin Endocrinol (Oxford) 2008;68:3:473-480.
  33. Alexopoulou O., Abrams P., Verhelst J. et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004;151:3:317-324.
  34. Ronchi C.L., Boschetti M., Degli Uberti E.C. et al. Efficacy of slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxford) 2007;67:4:512-519.
  35. Caron P., Bex M., Cullen D.R. et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxford) 2004;60:6:734-740.
  36. Abrams P., Alexopoulou O., Abs R. et al. Optimization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol 2007;157:5:571-577.
  37. Colao A., Ferone D., Lastoria S. et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 1996;81:6:2356-2362.
  38. Cozzi R., Attanasio R., Montini M. et al. Four-years treatment with octreotide-LAR in 110 acromegalic patients: the predictive value of short-term results? J Clin Endocrinol Metab 2003;88:7:3090-3098.
  39. Murray R.D., Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2009;93:8:2957-2968.
  40. Bronstein M.D. Acromegaly: molecular expression of somatostatin receptor sybtypes and treatment outcome. Front Horm Res 2006;35:129-134.
  41. Astruc B., Marbach P., Bouterfa H. et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol 2005;45:7:836-844.
  42. Melmed S., Colao A., Barkan A. et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009;94:5:1509-1517.


Abstract - 1507




Copyright (c) 2010 Ilovaĭskaia I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies